β-TrCP1 degradation is a novel action mechanism of PI3K/mTOR inhibitors in triple-negative breast cancer cells. [electronic resource]
Producer: 20150916Description: e143 p. digitalISSN:- 2092-6413
- Cell Line, Tumor
- Cell Proliferation
- Cell Survival -- drug effects
- Cyclin E -- genetics
- Dose-Response Relationship, Drug
- Female
- Furans -- pharmacology
- Gene Knockdown Techniques
- Humans
- Mechanistic Target of Rapamycin Complex 2
- Models, Biological
- Multiprotein Complexes -- antagonists & inhibitors
- Phosphoinositide-3 Kinase Inhibitors
- Phosphorylation -- drug effects
- Protein Kinase Inhibitors -- pharmacology
- Proteolysis -- drug effects
- Proto-Oncogene Proteins c-myc -- genetics
- Pyridines -- pharmacology
- Pyrimidines -- pharmacology
- TOR Serine-Threonine Kinases -- antagonists & inhibitors
- Triple Negative Breast Neoplasms -- genetics
- beta-Transducin Repeat-Containing Proteins -- genetics
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.